Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10316/109506 https://doi.org/10.1155/2014/538737 |
Resumo: | This study aimed to evaluate the efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in preventing the deleterious effects of diabetes on the kidney in an animal model of type 2 diabetes mellitus; the Zucker diabetic fatty (ZDF) rat: 20-week-old rats were treated with sitagliptin (10 mg/kg bw/day) during 6 weeks. Glycaemia and blood HbA1c levels were monitored, as well as kidney function and lesions. Kidney mRNA and/or protein content/distribution of DPP-IV, GLP-1, GLP-1R, TNF-α, IL-1β, BAX, Bcl-2, and Bid were evaluated by RT-PCR and/or western blotting/immunohistochemistry. Sitagliptin treatment improved glycaemic control, as reflected by the significantly reduced levels of glycaemia and HbA1c (by about 22.5% and 1.2%, resp.) and ameliorated tubulointerstitial and glomerular lesions. Sitagliptin prevented the diabetes-induced increase in DPP-IV levels and the decrease in GLP-1 levels in kidney. Sitagliptin increased colocalization of GLP-1 and GLP-1R in the diabetic kidney. Sitagliptin also decreased IL-1β and TNF-α levels, as well as, prevented the increase of BAX/Bcl-2 ratio, Bid protein levels, and TUNEL-positive cells which indicates protective effects against inflammation and proapoptotic state in the kidney of diabetic rats, respectively. In conclusion, sitagliptin might have a major role in preventing diabetic nephropathy evolution due to anti-inflammatory and antiapoptotic properties. |
id |
RCAP_0a10ce8e77ff5124542626efc60fb413 |
---|---|
oai_identifier_str |
oai:estudogeral.uc.pt:10316/109506 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animalsAnimalsApoptosisDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide 1InflammationKidneyPyrazinesRatsRats, ZuckerSitagliptin PhosphateTriazolesTumor Necrosis Factor-alphaThis study aimed to evaluate the efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in preventing the deleterious effects of diabetes on the kidney in an animal model of type 2 diabetes mellitus; the Zucker diabetic fatty (ZDF) rat: 20-week-old rats were treated with sitagliptin (10 mg/kg bw/day) during 6 weeks. Glycaemia and blood HbA1c levels were monitored, as well as kidney function and lesions. Kidney mRNA and/or protein content/distribution of DPP-IV, GLP-1, GLP-1R, TNF-α, IL-1β, BAX, Bcl-2, and Bid were evaluated by RT-PCR and/or western blotting/immunohistochemistry. Sitagliptin treatment improved glycaemic control, as reflected by the significantly reduced levels of glycaemia and HbA1c (by about 22.5% and 1.2%, resp.) and ameliorated tubulointerstitial and glomerular lesions. Sitagliptin prevented the diabetes-induced increase in DPP-IV levels and the decrease in GLP-1 levels in kidney. Sitagliptin increased colocalization of GLP-1 and GLP-1R in the diabetic kidney. Sitagliptin also decreased IL-1β and TNF-α levels, as well as, prevented the increase of BAX/Bcl-2 ratio, Bid protein levels, and TUNEL-positive cells which indicates protective effects against inflammation and proapoptotic state in the kidney of diabetic rats, respectively. In conclusion, sitagliptin might have a major role in preventing diabetic nephropathy evolution due to anti-inflammatory and antiapoptotic properties.Hindawi2014info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/109506http://hdl.handle.net/10316/109506https://doi.org/10.1155/2014/538737eng0962-93511466-1861Marques, CatarinaMega, CristinaGonçalves, AndreiaRodrigues-Santos, PauloLemos, Edite Teixeira deTeixeira, FredericoFontes-Ribeiro, Carlos A.Reis, F.Fernandes, Rosainfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-10-18T09:39:40Zoai:estudogeral.uc.pt:10316/109506Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:25:41.535231Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals |
title |
Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals |
spellingShingle |
Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals Marques, Catarina Animals Apoptosis Diabetes Mellitus, Experimental Diabetes Mellitus, Type 2 Dipeptidyl-Peptidase IV Inhibitors Glucagon-Like Peptide 1 Inflammation Kidney Pyrazines Rats Rats, Zucker Sitagliptin Phosphate Triazoles Tumor Necrosis Factor-alpha |
title_short |
Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals |
title_full |
Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals |
title_fullStr |
Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals |
title_full_unstemmed |
Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals |
title_sort |
Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals |
author |
Marques, Catarina |
author_facet |
Marques, Catarina Mega, Cristina Gonçalves, Andreia Rodrigues-Santos, Paulo Lemos, Edite Teixeira de Teixeira, Frederico Fontes-Ribeiro, Carlos A. Reis, F. Fernandes, Rosa |
author_role |
author |
author2 |
Mega, Cristina Gonçalves, Andreia Rodrigues-Santos, Paulo Lemos, Edite Teixeira de Teixeira, Frederico Fontes-Ribeiro, Carlos A. Reis, F. Fernandes, Rosa |
author2_role |
author author author author author author author author |
dc.contributor.author.fl_str_mv |
Marques, Catarina Mega, Cristina Gonçalves, Andreia Rodrigues-Santos, Paulo Lemos, Edite Teixeira de Teixeira, Frederico Fontes-Ribeiro, Carlos A. Reis, F. Fernandes, Rosa |
dc.subject.por.fl_str_mv |
Animals Apoptosis Diabetes Mellitus, Experimental Diabetes Mellitus, Type 2 Dipeptidyl-Peptidase IV Inhibitors Glucagon-Like Peptide 1 Inflammation Kidney Pyrazines Rats Rats, Zucker Sitagliptin Phosphate Triazoles Tumor Necrosis Factor-alpha |
topic |
Animals Apoptosis Diabetes Mellitus, Experimental Diabetes Mellitus, Type 2 Dipeptidyl-Peptidase IV Inhibitors Glucagon-Like Peptide 1 Inflammation Kidney Pyrazines Rats Rats, Zucker Sitagliptin Phosphate Triazoles Tumor Necrosis Factor-alpha |
description |
This study aimed to evaluate the efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in preventing the deleterious effects of diabetes on the kidney in an animal model of type 2 diabetes mellitus; the Zucker diabetic fatty (ZDF) rat: 20-week-old rats were treated with sitagliptin (10 mg/kg bw/day) during 6 weeks. Glycaemia and blood HbA1c levels were monitored, as well as kidney function and lesions. Kidney mRNA and/or protein content/distribution of DPP-IV, GLP-1, GLP-1R, TNF-α, IL-1β, BAX, Bcl-2, and Bid were evaluated by RT-PCR and/or western blotting/immunohistochemistry. Sitagliptin treatment improved glycaemic control, as reflected by the significantly reduced levels of glycaemia and HbA1c (by about 22.5% and 1.2%, resp.) and ameliorated tubulointerstitial and glomerular lesions. Sitagliptin prevented the diabetes-induced increase in DPP-IV levels and the decrease in GLP-1 levels in kidney. Sitagliptin increased colocalization of GLP-1 and GLP-1R in the diabetic kidney. Sitagliptin also decreased IL-1β and TNF-α levels, as well as, prevented the increase of BAX/Bcl-2 ratio, Bid protein levels, and TUNEL-positive cells which indicates protective effects against inflammation and proapoptotic state in the kidney of diabetic rats, respectively. In conclusion, sitagliptin might have a major role in preventing diabetic nephropathy evolution due to anti-inflammatory and antiapoptotic properties. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10316/109506 http://hdl.handle.net/10316/109506 https://doi.org/10.1155/2014/538737 |
url |
http://hdl.handle.net/10316/109506 https://doi.org/10.1155/2014/538737 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
0962-9351 1466-1861 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Hindawi |
publisher.none.fl_str_mv |
Hindawi |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799134138889928704 |